CliffBio
biologic

Aucatzyl

Obecabtagene autoleucel

Loss of exclusivityNovember 2036FDA regulatory exclusivity expiry
CompanyAutolus Therapeutics →View the full company profile on CliffBio

Drug detail

Brand nameAucatzyl
Active ingredientObecabtagene autoleucel
Strength410 × 10^6CAR+ T CELLS TOTAL; DELIVERED AS A SPLIT DOSE IN 3-5 BAGS ON DAY 1 & 10
Dosage formSuspension
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2024
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Aucatzyl patent cliff — loss of exclusivity November 2036 | CliffBio